Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DERMNASDAQ:LIANNASDAQ:MOLNNYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDERMJourney Medical$7.00+2.6%$6.56$3.46▼$8.24$161.73M0.8683,916 shs64,670 shsLIANLianBio$0.38$0.21$0.27▼$4.99$41.06M0.231.04 million shs25,804 shsMOLNMolecular Partners$4.05+4.2%$3.94$3.36▼$12.70$163.68M1.1521,031 shs10,089 shsPRMEPrime Medicine$1.29+4.9%$1.53$1.11▼$8.14$169.37M1.91.33 million shs2.00 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDERMJourney Medical+0.59%-3.94%-7.71%+31.41%+92.11%LIANLianBio0.00%+90.10%+90.00%+85.37%+21.33%MOLNMolecular Partners-1.77%+1.28%+0.26%-19.31%+2.37%PRMEPrime Medicine+5.58%-2.38%-27.22%-58.45%-83.49%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDERMJourney Medical1.8668 of 5 stars3.62.00.00.01.01.70.6LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/AMOLNMolecular Partners2.1819 of 5 stars3.82.00.00.03.30.00.6PRMEPrime Medicine3.6957 of 5 stars4.40.00.00.02.33.31.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDERMJourney Medical 3.20Buy$9.8841.07% UpsideLIANLianBio 0.00N/AN/AN/AMOLNMolecular Partners 3.50Strong Buy$12.00196.00% UpsidePRMEPrime Medicine 2.86Moderate Buy$11.80814.73% UpsideCurrent Analyst Ratings BreakdownLatest LIAN, MOLN, DERM, and PRME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.005/15/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/27/2025DERMJourney MedicalIndustrial Alliance SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$10.503/27/2025DERMJourney MedicalAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/20/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.003/19/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/18/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $13.003/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.00(Data available from 5/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDERMJourney Medical$56.24M2.88$0.25 per share28.37$1.05 per share6.67LIANLianBioN/AN/AN/AN/A$2.71 per shareN/AMOLNMolecular Partners$2.23M73.33N/AN/A$5.41 per share0.75PRMEPrime Medicine$3.85M44.04N/AN/A$1.37 per share0.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDERMJourney Medical-$3.85M-$0.39N/AN/AN/A-31.74%-132.10%-26.90%8/11/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/AMOLNMolecular Partners-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ALatest LIAN, MOLN, DERM, and PRME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/14/2025Q1 2025DERMJourney Medical-$0.24-$0.18+$0.06-$0.18$12.05 million$13.14 million3/26/2025Q4 2024DERMJourney Medical-$0.22$0.08+$0.30$0.08$14.21 million$14.30 million3/7/2025Full YearPRMEPrime MedicineN/A-$1.65N/AN/AN/AN/A3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDERMJourney MedicalN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/APRMEPrime Medicine$1.45112.09%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDERMJourney Medical1.811.381.03LIANLianBioN/A10.0610.06MOLNMolecular PartnersN/A14.3314.33PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDERMJourney Medical7.25%LIANLianBio74.85%MOLNMolecular Partners26.55%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipDERMJourney Medical15.03%LIANLianBio7.59%MOLNMolecular Partners5.93%PRMEPrime Medicine23.47%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDERMJourney Medical9023.10 million18.14 millionN/ALIANLianBio110108.06 million99.86 millionNot OptionableMOLNMolecular Partners18040.38 million37.97 millionNot OptionablePRMEPrime Medicine234131.29 million100.38 millionOptionableLIAN, MOLN, DERM, and PRME HeadlinesRecent News About These CompaniesWedbush Has Bullish Estimate for Prime Medicine Q3 EarningsMay 23 at 8:07 AM | marketbeat.comWestwood Holdings Group Inc. Increases Stake in Prime Medicine, Inc. (NYSE:PRME)May 23 at 5:58 AM | marketbeat.comWhat is Wedbush's Estimate for Prime Medicine Q3 Earnings?May 23 at 2:43 AM | americanbankingnews.comPrime Medicine (NYSE:PRME) Stock Rating Lowered by HC WainwrightMay 23 at 1:59 AM | americanbankingnews.comPrime Medicine's (PRME) "Neutral" Rating Reiterated at JPMorgan Chase & Co.May 23 at 1:59 AM | americanbankingnews.comPrime Medicine (NYSE:PRME) Downgraded to "Neutral" Rating by HC WainwrightMay 22 at 8:22 AM | marketbeat.comPrime Medicine's (PRME) Neutral Rating Reaffirmed at JPMorgan Chase & Co.May 22 at 8:22 AM | marketbeat.comPrime Medicine (NYSE:PRME) Given New $6.00 Price Target at JMP SecuritiesMay 22 at 3:31 AM | americanbankingnews.com6 Analysts Assess Prime Medicine: What You Need To KnowMay 21 at 7:17 PM | nasdaq.comChardan Capital Issues Pessimistic Forecast for Prime Medicine (NYSE:PRME) Stock PriceMay 21 at 4:15 AM | americanbankingnews.comCEO among 25% of staff out the door at cash-strapped PrimeMay 20 at 1:29 PM | thepharmaletter.comPrime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staffMay 20 at 3:28 AM | fiercebiotech.comPrime Medicine claims ‘proof of concept,’ but lays off staff in pivotMay 20 at 3:28 AM | biopharmadive.comCRISPR pioneer Prime Medicine switches CEO and lays off quarter of its staffMay 20 at 3:28 AM | bostonglobe.comPrime Medicine drops after cutting CGD program amid restructuringMay 20 at 3:28 AM | msn.comPrime Medicine stock plummets amid restructuring and leadership changesMay 20 at 3:28 AM | msn.comPrime Medicine Announces Layoffs, CEO Transition: Retail Gets More BullishMay 20 at 3:28 AM | msn.comHead to Head Review: Prime Medicine (NYSE:PRME) and BioCryst Pharmaceuticals (NASDAQ:BCRX)May 20 at 1:47 AM | americanbankingnews.comPrime Medicine, Inc.: Strategic Shifts and Leadership Changes Bolster Long-term Buy Rating Amid Near-term VolatilityMay 19, 2025 | tipranks.comPrime Medicine Appoints New CEO Amid RestructuringMay 19, 2025 | tipranks.comPrime Medicine, Inc. Announces Positive Phase 1/2 Data for PM359 and Strategic Restructuring Focused on Liver Disease ProgramsMay 19, 2025 | quiverquant.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLIAN, MOLN, DERM, and PRME Company DescriptionsJourney Medical NASDAQ:DERM$7.00 +0.18 (+2.64%) Closing price 04:00 PM EasternExtended Trading$7.01 +0.01 (+0.14%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.LianBio NASDAQ:LIAN$0.38 0.00 (0.00%) As of 05/21/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.Molecular Partners NASDAQ:MOLN$4.05 +0.16 (+4.22%) Closing price 03:56 PM EasternExtended Trading$4.06 +0.00 (+0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Prime Medicine NYSE:PRME$1.29 +0.06 (+4.88%) Closing price 04:00 PM EasternExtended Trading$1.28 -0.01 (-1.09%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
